No headlines found.
Globe Newswire (Thu, 14-Mar 9:00 AM ET)
Globe Newswire (Wed, 13-Mar 9:00 AM ET)
ACCESSWIRE (Tue, 12-Mar 8:03 AM ET)
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
ACCESSWIRE (Mon, 4-Mar 8:05 AM ET)
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
Globe Newswire (Thu, 22-Feb 7:00 AM ET)
Globe Newswire (Thu, 15-Feb 9:00 AM ET)
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
Globe Newswire (Tue, 13-Feb 9:00 AM ET)
Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream
Globe Newswire (Wed, 10-Jan 7:00 AM ET)
Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now
Globe Newswire (Tue, 9-Jan 7:00 AM ET)
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
Globe Newswire (Mon, 8-Jan 9:43 AM ET)
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
Neurometrix trades on the NASDAQ stock market under the symbol NURO.
As of March 27, 2024, NURO stock price climbed to $4.16 with 2,141 million shares trading.
NURO has a beta of 1.06, meaning it tends to be more sensitive to market movements. NURO has a correlation of 0.05 to the broad based SPY ETF.
NURO has a market cap of $8.26 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, NURO stock traded as high as $310.00 and as low as $2.70.
The top ETF exchange traded funds that NURO belongs to (by Net Assets): VXF.
NURO has underperformed the market in the last year with a return of -63.9%, while the SPY ETF gained +33.6%. In the last 3 month period, NURO fell short of the market, returning +9.9%, while SPY returned +10.1%. However, in the most recent 2 weeks NURO has outperformed the stock market by returning +6.1%, while SPY returned +1.7%.
NURO support price is $3.80 and resistance is $4.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NURO stock will trade within this expected range on the day.